Joint Programming Initiative on Antimicrobial Resistance

Research call: One Health interventions to prevent or reduce the development and transmission of AMR

JPIAMR is launching an international call for projects under the umbrella of the JPIAMR and within the framework of the ERA-NET JPIAMR-ACTION. The call, with financial support from the European Commission, includes 30 funding organisations from 21 JPIAMR member countries, see complete list below. The total estimated call budget is 24.9 million Euro.

Timeline

The call One Health interventions to prevent or reduce the development and transmission of AMR has a two-step procedure.

14 January 2021 (11.00 CET) – Call opens

16 March 2021 (12.00 CET) – Deadline pre-proposals

12 July 2021 – Deadline full proposals

Please contact the call secretariat if you have any questions about the call: JPI-AMRCalls@agencerecherche.fr

Information and application

Webinar for applicants

A live webinar was held on the 28th of January 2021 presenting the call and the partner search tool. Representatives from funders participating in the call answered questions live.

The presentations from the webinar are now published on the JPIAMR YouTube channel.

A summary of the Q&A can be found here: Q&A Online Webinar for applicants 28 January 2021

Partner Search Tool

A match-making tool has been created for applicants, to facilitate networking and the creation of consortia.

The tool can be consulted for several purposes:

  • Partner looking for project: As individual researcher or a representative of a lab or research team, searching for a project to join.
  • Project looking for partner: If you want to build a consortium around an existing project and want to find partners for your project ideas.

Link to tool : https://ncn.gov.pl/partners/amr13th/

Context of call

With the current focus of the JPIAMR Strategic Research and Innovation Agenda, this call will specifically focus on tackling the rising threat of antibiotic resistance. Addressing the rising threat of antibiotic resistance requires a One Health approach since resistant bacteria, genetic elements and antibiotics are found in humans, animals and the environment. Declining clinical effectiveness of existing antibiotics together with the low and insufficient number of promising new antibiotics in the pipeline stresses the urgency to understand the mechanisms of emergence and transmission of antibiotic resistance. The European One Health Action Plan against AMR  encourages the EU and its Member States to deliver innovative, effective and sustainable responses to AMR, especially to reduce the emergence and spread of AMR inside and outside the EU.

Through this call, the ERA-NET JPIAMR-ACTION intends to create and reinforce the collaboration between research partners coming from different countries and different fields of expertise to promote research on antibiotic resistance.

Topic of the call

Proposals should aim to either:

  • Understand the impact of interventions on the development and transmission of antibiotic resistance in, and/or between, at least two One Health settings;

OR

  • Design, implement, evaluate, and/or compare innovative interventions to control the development and transmission of antibiotic resistance in, and/or between, at least two One Health settings.

As stated, research proposals must focus on at least two out of the three “One-Health” settings, being: Human Health, Animal Health, and Environment. Participation of low and middle income countries is encouraged.

Eligibility

Consortia should consists of a maximum of six (6) project partners (including non-funded partners). The maximum number of partners can be increased to seven (7) if the consortium includes a partner coming from either low and middle income countries, or from Hungary, Latvia, Lithuania and Poland. The budget of non-funded partners shall not exceed 30% of the total transnational project budget requested. Furthermore, consortia should always consist of a majority of project partners eligible for funding. Funding is granted for a maximum of three (3) years in accordance with national regulations and applicable legal provisions.

Participating agencies and organisations

  • Argentina – Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)
  • Belgium – Fonds voor Wetenschappelijk onderzoek-Vlaanderen (FWO)
  • Belgium – Fonds de la Recherche Scientifique (FNRS)
  • Canada – Canadian Institutes of Health Research (CIHR)
  • Canada – International Development Research Centre (IDRC)
  • Denmark – International Centre for Antimicrobial Resistance Solutions (ICARS)
  • Denmark – Innovationsfonden (IFD)
  • Estonia – Estonian Research Council (ETAg)
  • Finland – Suomen Akatemia (AKA)
  • France – Agence Nationale de la Recherche (ANR)
  • Germany – Federal Ministry of Education and Research (BMBF)
  • Hungary – National Research, Development and Innovation Office (NKFIH)
  • Ireland – The Health Research Board (HRB)
  • Ireland – Department of Agriculture, Food and the Marine (DAFM)
  • Israel – Ministry of Health (CSO-MOH)
  • Italy – Fondazione Regionale per la Ricerca Biomedica (FRRB)
  • Italy – Ministero della Salute (It-MoH)
  • Latvia – Valsts Izglitibas Attistibas Agentura (VIAA)
  • Lithuania – Research Council of Lithuania (RCL)
  • Moldova – Agentia Nationala Pentru Cercetare Si Dezvoltare (ANCD)
  • Netherlands – Zorgonderzoek Nederland Zon (ZonMw)
  • Norway – Research Council of Norway (RCN)
  • Poland – Narodowe Centrum Nauki (NCN)
  • Spain – Agencia Estatal de Investgacion (AEI)
  • Spain – Instituto de Salud Carlos III (ISCIII)
  • Sweden – Swedish Research Council (SRC)
  • Sweden – Swedish International Development Cooperation Agency (Sida)
  • United Kingdom – Medical Research Council (MRC)
  • United Kingdom – Biotechnology and Biological Sciences Research Council (BBSRC)
  • United Kingdom – Natural Environment Research Council (NERC)